Evaluation of the Artus® CMV PCR Test

The human Cytomegalovirus (CMV) is found in blood, tissues and nearly all secretory fluids
of infected persons. Transmission can be oral, sexual, via blood transfusion, organ
transplantation, intrauterine, or perinatal. Infection with CMV preadolescence frequently
leads to an asymptomatic infection followed by a lifelong persistence of the virus in the
body. Infection post adolescence typically leads to symptoms that resemble those of
mononucleosis (e.g., fever, fatigue, hepatitis, etc.) In contrast, CMV infections in immune
compromised patients can be life threatening. A major cause of virus-associated morbidity
and mortality in solid organ transplantation patients is illness caused by CMV (i.e., CMV
syndrome or CMV disease).

The risk of progressing to CMV disease post-transplant is strongly correlated with the
serological status of the donor (D) and recipient (R); the highest risk group is R-/D+.
Patients at risk for CMV disease can be managed either preemptively (i.e., patients are only
treated with antiviral agents after evidence of CMV infection arises), or prophylactically
(i.e., all patients are treated with antiviral agents regardless of CMV infection status).
Monitoring of the CMV viral load of transplant patients during antiviral therapy provides an
effective aid in the management of patients with CMV disease. The artus® CMV RG PCR test is
a nucleic acid amplification-based assay for the quantitation of CMV DNA using PCR in the
Rotor-Gene™ 6000 Instrument (also known as Rotor-Gene Q) with software version 2.0.2.3 or
higher. In the present study the artus CMV RG PCR test result will be evaluated for its
ability to safely and effectively monitor transplant patients during antiviral therapy and
will be compared to the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test

Inclusion Criteria:

1. Subjects must have had a kidney transplant.

2. Subjects that present at a hospital, clinic or physicians office for
post-transplantation care.

3. Subjects must be 18 years of age or older.

4. Subjects providing informed consent.

5. Subjects must have a CMV infection as demonstrated by a positive result by the site's
CMV-PCR-Laboratory Developed Test (CMV-PCR-LDT)

6. Subjects must be candidates for, and will be treated with ganciclovir and/or
valganciclovir antiviral therapy.

Exclusion Criteria:

1. Subjects wherein the HIV status is positive.

2. Specimens with less than 1.0 ml EDTA plasma for artus testing.

3. Subjects from whom samples were collected, handled and/or stored inappropriately
and/or determined to be unsatisfactory for processing/testing with the artus CMV RG
PCR test (for which an explanation is provided in the case of subject exclusion).

EDTA plasma specimens that have been stored inappropriately which include the
following storage conditions: whole blood that has been frozen; whole blood processed
for plasma more than 24 hours after collection; plasma stored at room temperature for
more than 24 hours or 4C for more than 5 days at -20C for more than 6 months; frozen
plasma with more than two freeze thaw cycles;

Extracted nucleic acid that has been stored inappropriately which include the
following storage conditions: extracted DNA stored for more than 5 days at -20C, or
longer than six months at -20C; frozen nucleic acid with more than two freeze/thaw
cycles.

4. Specimens that have been stored inappropriately for testing with that test used by
the site to demonstrate a CMV infection. (A site specific memo will be provided to
QIAGEN on appropriate specimen storage conditions.)